• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Churchill Capital Corp XI filed SEC Form 8-K: Financial Statements and Exhibits

    3/17/26 5:00:08 PM ET
    $CCXI
    Get the next $CCXI alert in real time by email
    false 0002074973 0002074973 2026-03-17 2026-03-17 0002074973 CCXI:UnitsEachConsistingOfOneClassOrdinaryShareAndOnetenthOfOneRedeemableWarrantMember 2026-03-17 2026-03-17 0002074973 CCXI:ClassOrdinarySharesParValue0.0001PerShareMember 2026-03-17 2026-03-17 0002074973 CCXI:WarrantsEachWholeWarrantExercisableForOneClassOrdinaryShareAtExercisePriceOf11.50PerShareMember 2026-03-17 2026-03-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    PURSUANT TO SECTION 13 OR 15(d)

    OF THE SECURITIES EXCHANGE ACT OF 1934

     

    Date of Report (Date of earliest event reported): March 17, 2026

     

    CHURCHILL CAPITAL CORP XI

    (Exact name of registrant as specified in its charter)

     

    Cayman Islands   001-43020   86-1959629
    (State or other jurisdiction
    of incorporation)
      (Commission File Number)   (IRS Employer
    Identification No.)

     

    640 Fifth Avenue, 14th Floor

    New York, NY 10019

    (Address of principal executive offices, including zip code)

     

    Registrant’s telephone number, including area code: (212) 380-7500

     

    Not Applicable

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Units, each consisting of one Class A ordinary share and one-tenth of one redeemable warrant   CCXIU   The Nasdaq Stock Market LLC
    Class A ordinary shares, par value $0.0001 per share   CCXI   The Nasdaq Stock Market LLC
    Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share   CCXIW   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ 

     

     

      

     

     

     

    Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

     

    Appointment of New Directors

     

    On March 17, 2026, the board of directors (the “Board”) of Churchill Capital Corp XI (the “Company”) appointed each of Paul Lapping and Stephen Murphy as a director of the Board, effective immediately. The Board also appointed each of Messrs. Lapping and Murphy as a member of the compensation committee and the audit committee of the Board (the “Audit Committee”) and Mr. Lapping as the chairperson of the Audit Committee, replacing William Sherman, who had served as the interim chairperson of the Audit Committee. Mr. Sherman will continue to serve as a member of the Audit Committee. Each of Messrs. Lapping and Murphy will serve as a member of the first class of directors, which term will expire at the Company’s first annual general meeting.

     

    Paul D. Lapping, age 63, is the Manager of Jakal Investments, LLC, a private investment firm he founded in 2005 that focuses on technology, healthcare, fintech, and artificial intelligence sectors. Since April 2015, he has also served as the Manager of Green Pastures Management, LLC, a series LLC with underlying LLC investment vehicles, where he manages and oversees the investment activities of the series and underlying vehicles. He has served as a director of Churchill Capital Corp IX (Nasdaq: CCIX) (“Churchill IX”), a special purpose acquisition company (“SPAC”), since April 2025. From August 2025 to February 2026, he also served as a director of Churchill Capital Corp X (“Churchill X”), a SPAC that completed its business combination with Infleqtion, Inc. in February 2026. From 2011 to 2012, Mr. Lapping served as Chief Operating Officer of SuRo Capital Corp. (Nasdaq: SSSS), a publicly traded, growth-stage venture capital firm (“Suro”). Prior to Suro, Mr. Lapping served as a director and Chief Financial Officer of New University Holdings Corp., a capital pool company listed on the TSX Venture Exchange, from August 2010 to August 2011. From October 2009 to May 2011, Mr. Lapping was Chief Financial Officer, Treasurer, Secretary, and a director of 57th Street General Acquisition Corp., a SPAC. Between 2007 and 2009, he served as Chief Financial Officer, Treasurer, and Secretary of Alternative Asset Management Acquisition Corp., also a SPAC. From 1995 to 2003, Mr. Lapping was a General Partner of Minotaur Partners II, L.P. and Merchant Partners, L.P., private equity partnerships focused on middle-market investments. From 1991 to 1995, Mr. Lapping led corporate development at Montgomery Ward Holding Corp., a diversified retail and direct marketing company. From 1988 to 1991, Mr. Lapping worked at Farley Industries, Inc. and its affiliated companies (including Fruit of the Loom, Inc. and West Point-Pepperell, Inc.) in corporate development and finance roles. Earlier in his career, Mr. Lapping worked with Golder, Thoma and Cressey, a private equity firm, and in the mergers and acquisitions group at Salomon Brothers Inc. Mr. Lapping is a Certified Public Accountant. He holds a Bachelor of Science degree from the University of Illinois and an M.B.A. from the J.L. Kellogg Graduate School of Management at Northwestern University. Mr. Lapping is well-qualified to serve as a member of the Board due to his significant operational, financial and leadership experience and experience serving on SPAC boards.

     

    Stephen Murphy, age 62, has served as the Co-Founding Partner of Merivel Capital Partners LLP, a boutique private placement group authorized by the UK FCA, since 2023. Since 2010, Mr. Murphy has also served as Chairman of “Budd – London” as well as a director of numerous other luxury goods manufacturers and retailers including Brown Thomas Group (Ireland), H Huntsman & Sons Limited (UK), “The Watch Gallery” UK and J. R. Tusting & Company (UK). Mr. Murphy has significant past investment banking, principal investing, and direct entrepreneurial experience across a wide range of industries and is actively involved in a number of international businesses at board levels. He has served as a director of Churchill IX since May 2024. He also served as a director of Churchill X from August 2025 to the completion of its business combination in February 2026, and served as a director of Churchill Capital Corp VI and VII from 2021 until their respective liquidations. Mr. Murphy is also an active angel investor. Mr. Murphy serves as a director of various companies related to Qalaa Holdings SAE, which is involved in energy and infrastructure investments in Egypt. Mr. Murphy was trained as a financial analyst in New York starting in 1986 and ultimately was made head of Salomon Brothers International’s M&A Group in London. He went on to become a Managing Director of Citigroup International. As a Managing Director of Citigroup International, Mr. Murphy was involved in the evaluation and execution of private and public financings and capital raising. Mr. Murphy received an M.A. from University of Dublin Trinity College. Mr. Murphy is well-qualified to serve as a member of the Board due to his significant financial and leadership experience and experience serving on SPAC boards.

     

    No family relationships exist between Mr. Lapping, Mr. Murphy and any other directors or executive officers of the Company. Neither Mr. Lapping nor Mr. Murphy is a party to any arrangements with any other person pursuant to which he was nominated as a director. There are no transactions to which the Company is or was a participant and in which Mr. Lapping or Mr. Murphy has a material interest subject to disclosure under Item 404(a) of Regulation S-K.

     

    1

     

     

    In connection with their appointments, each of Mr. Lapping and Mr. Murphy signed a joinder to that certain letter agreement dated as of December 16, 2025, by and among the Company, its officers, its directors and Churchill Sponsor XI LLC, pursuant to which, among other things, the signatories agreed to waive certain redemption rights and to vote any ordinary shares of the Company they hold in favor of an initial business combination. Each of Mr. Lapping and Mr. Murphy also entered into a standard director indemnity agreement with the Company, a form of which was filed as Exhibit 10.7 to the Company’s Registration Statement on Form S-1 filed with the SEC on November 18, 2025.

     

    Director Compensation Agreements

     

    On March 17, 2026, the Company entered into a director agreement (“Director Agreement”) with each of Mr. Sherman, Mr. Lapping and Mr. Murphy, pursuant to which, in connection with each director’s continuing service as a director of the Company, the Company agreed to pay each director cash compensation of $75,000 per annum, beginning on April 1, 2026.

     

    The foregoing summary of the Director Agreements does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Director Agreements, a form of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.

     

    Item 9.01. Financial Statements and Exhibits.

     

    (d)  Exhibits

     

    Exhibit No.   Description
    10.1   Form of Director Agreement.
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

     

    2

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      CHURCHILL CAPITAL CORP XI
           
    Date: March 17, 2026 By: /s/ Jay Taragin
        Name:  Jay Taragin
        Title: Chief Financial Officer

     

    3

     

    Get the next $CCXI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CCXI

    DatePrice TargetRatingAnalyst
    8/4/2022$81.00Buy
    Canaccord Genuity
    11/10/2021$107.00 → $110.00Strong Buy
    Raymond James
    10/11/2021$14.00 → $38.00Underweight → Neutral
    JP Morgan
    10/11/2021$64.00Mkt Perform → Outperform
    SVB Leerink
    10/11/2021$62.00 → $107.00Outperform → Strong Buy
    Raymond James
    10/8/2021$62.00 → $107.00Outperform → Strong Buy
    Raymond James
    10/8/2021Neutral → Overweight
    Piper Sandler
    7/7/2021$26.00 → $31.00Hold → Buy
    Stifel
    More analyst ratings

    $CCXI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Canaccord Genuity resumed coverage on ChemoCentryx with a new price target

    Canaccord Genuity resumed coverage of ChemoCentryx with a rating of Buy and set a new price target of $81.00

    8/4/22 8:51:51 AM ET
    $CCXI

    Raymond James reiterated coverage on ChemoCentryx with a new price target

    Raymond James reiterated coverage of ChemoCentryx with a rating of Strong Buy and set a new price target of $110.00 from $107.00 previously

    11/10/21 9:06:49 AM ET
    $CCXI

    ChemoCentryx upgraded by JP Morgan with a new price target

    JP Morgan upgraded ChemoCentryx from Underweight to Neutral and set a new price target of $38.00 from $14.00 previously

    10/11/21 8:32:48 AM ET
    $CCXI

    $CCXI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Churchill Capital Corp XI Announces the Separate Trading of its Class A Ordinary Shares and Warrants, Commencing February 9, 2026

    New York, NY, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Churchill Capital Corp XI (NASDAQ:CCXIU) (the "Company") announced today that, commencing February 9, 2026, holders of the units sold in the Company's initial public offering may elect to separately trade the Company's Class A ordinary shares and warrants included in the units. No fractional warrants will be issued upon separation of the units and only whole warrants will trade. The Class A ordinary shares and warrants that are separated will trade on the Nasdaq Global Market under the symbols "CCXI" and "CCXIW," respectively. Those units not separated will continue to trade on the Nasdaq Global Market under the symbol "CCXIU." This press re

    2/5/26 4:28:00 PM ET
    $CCXI

    AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX

    TAVNEOS® (avacopan), a First-in-Class Medicine for Patients With Severe Active ANCA-Associated Vasculitis, Added to Inflammation Portfolio THOUSAND OAKS, Calif., Oct. 20, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it has successfully completed its previously announced acquisition of ChemoCentryx, Inc. (NASDAQ:CCXI), a biopharmaceutical company focused on orally administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer, for $52 per share in cash, representing aggregate merger consideration of approximately $3.7 billion. "ChemoCentryx enhances Amgen's leading inflammation and nephrology portfolio and includes TAVNEOS® (avacopan), a first-in-cl

    10/20/22 9:05:00 AM ET
    $AMGN
    $CCXI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    ChemoCentryx Announces Presentations at the 2022 American Society of Nephrology and American College of Rheumatology Annual Meetings

    -- Planned posters and an oral presentation will highlight data from the trials that supported the approval of TAVNEOS® (avacopan) for patients with ANCA-associated vasculitis; additional poster will cover expression of kidney C5aR -- SAN CARLOS, Calif., Oct. 17, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ:CCXI), today announced planned presentations covering TAVNEOS® (avacopan), an orally administered selective complement 5a receptor (C5aR) inhibitor, at the American Society of Nephrology (ASN) Kidney Week 2022 and American College of Rheumatology (ACR) Convergence 2022 annual meetings taking place in November. American Society of Nephrology Kidney Week 2022, November 3-6, Orlan

    10/17/22 8:30:00 AM ET
    $CCXI

    $CCXI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $CCXI
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    Officer Klein Michael Stuart bought $5,000,000 worth of Class A Ordinary Shares (500,000 units at $10.00) (SEC Form 4)

    4 - Churchill Capital Corp XI (0002074973) (Issuer)

    12/19/25 5:16:36 PM ET
    $CCXI

    SEC Form 3 filed by new insider Klein Michael Stuart

    3 - Churchill Capital Corp XI (0002074973) (Issuer)

    12/16/25 9:40:41 PM ET
    $CCXI

    SEC Form 3 filed by new insider Sherman William M

    3 - Churchill Capital Corp XI (0002074973) (Issuer)

    12/16/25 9:40:10 PM ET
    $CCXI

    FDA Approval for TAVNEOS issued to CHEMOCENTRYX, INC.

    Submission status for CHEMOCENTRYX, INC.'s drug TAVNEOS (ORIG-1) with active ingredient AVACOPAN has changed to 'Approval' on 10/07/2021. Application Category: NDA, Application Number: 214487, Application Classification: Type 1 - New Molecular Entity

    10/15/21 3:42:50 PM ET
    $CCXI

    $CCXI
    SEC Filings

    View All

    Churchill Capital Corp XI filed SEC Form 8-K: Financial Statements and Exhibits

    8-K - Churchill Capital Corp XI (0002074973) (Filer)

    3/17/26 5:00:08 PM ET
    $CCXI

    SEC Form SCHEDULE 13G filed by Churchill Capital Corp XI

    SCHEDULE 13G - Churchill Capital Corp XI (0002074973) (Subject)

    2/17/26 4:00:12 PM ET
    $CCXI

    SEC Form SCHEDULE 13G filed by Churchill Capital Corp XI

    SCHEDULE 13G - Churchill Capital Corp XI (0002074973) (Subject)

    2/17/26 3:10:21 PM ET
    $CCXI

    $CCXI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Klein Michael Stuart bought $5,000,000 worth of Class A Ordinary Shares (500,000 units at $10.00) (SEC Form 4)

    4 - Churchill Capital Corp XI (0002074973) (Issuer)

    12/19/25 5:16:36 PM ET
    $CCXI

    $CCXI
    Leadership Updates

    Live Leadership Updates

    View All

    ChemoCentryx Announces Appointment of Jennifer L. Herron to Board as Independent Director

    SAN CARLOS, Calif., July 05, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ:CCXI), today announced that Jennifer L. Herron has been appointed to the Board as an independent director, effective June 28, 2022. With this appointment, the Board increases the number of directors constituting the whole Board from eight to nine. "With more than 25 years developing and refining her therapeutics commercial expertise, Jennifer is uniquely positioned to add immediate value to our TAVNEOS® (avacopan) commercial efforts," said Thomas J. Schall, Ph.D., President and Chief Executive Officer of ChemoCentryx. "Jennifer's values closely align with our organization, and we are confident this addition

    7/5/22 8:30:00 AM ET
    $CCXI

    ChemoCentryx Appoints Rita I. Jain, M.D. as Executive Vice President, Chief Medical Officer

    Appointment Brings More than 20 Years of Drug Development Experience as Company Launches First Product SAN CARLOS, Calif., Oct. 11, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ:CCXI), today announced the appointment of Rita I. Jain, M.D., as Executive Vice President, Chief Medical Officer. In this role, she will oversee development activities including clinical development, development operations, regulatory affairs, and drug safety and pharmacovigilance. Dr. Jain will continue to serve on the ChemoCentryx board of directors (where she has served since March of 2019) as an executive employee director. Dr. Jain, a board-certified rheumatologist, brings more than 20 years of drug de

    10/11/21 8:30:00 AM ET
    $CCXI

    ChemoCentryx Announces Appointment of Susan M. Kanaya to Board of Directors

    MOUNTAIN VIEW, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced the appointment of Susan M. Kanaya, the Company’s Executive Vice President and Chief Financial and Administrative Officer, to the ChemoCentryx Board of Directors effective March 2, 2021. “Susan Kanaya’s many fundamental contributions have been key to ChemoCentryx’s growth and prosperity,” said Thomas J. Schall, Ph.D., President and Chief Executive Officer of ChemoCentryx. “Over many formative years of our enterprise, she ensured our strong financial position, allowing us to achieve our operational plans and thus increasing shareholder value while serving patients’ needs. As a

    3/8/21 8:30:00 AM ET
    $CCXI

    $CCXI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by ChemoCentryx Inc. (Amendment)

    SC 13G/A - ChemoCentryx, Inc. (0001340652) (Subject)

    9/12/22 11:13:14 AM ET
    $CCXI

    SEC Form SC 13G/A filed by ChemoCentryx Inc. (Amendment)

    SC 13G/A - ChemoCentryx, Inc. (0001340652) (Subject)

    2/9/22 3:33:37 PM ET
    $CCXI

    SEC Form SC 13G/A filed by ChemoCentryx Inc. (Amendment)

    SC 13G/A - ChemoCentryx, Inc. (0001340652) (Subject)

    2/9/22 9:11:44 AM ET
    $CCXI

    $CCXI
    Financials

    Live finance-specific insights

    View All

    AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX

    TAVNEOS® (avacopan), a First-in-Class Medicine for Patients With Severe Active ANCA-Associated Vasculitis, Added to Inflammation Portfolio THOUSAND OAKS, Calif., Oct. 20, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it has successfully completed its previously announced acquisition of ChemoCentryx, Inc. (NASDAQ:CCXI), a biopharmaceutical company focused on orally administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer, for $52 per share in cash, representing aggregate merger consideration of approximately $3.7 billion. "ChemoCentryx enhances Amgen's leading inflammation and nephrology portfolio and includes TAVNEOS® (avacopan), a first-in-cl

    10/20/22 9:05:00 AM ET
    $AMGN
    $CCXI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    ChemoCentryx Cancels Second Quarter 2022 Financial Results Conference Call

    SAN CARLOS, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ:CCXI), today announced the cancellation of its second quarter 2022 financial results conference call scheduled for Tuesday, August 9, 2022, at 5:00 p.m. ET. The call is being cancelled due to the August 4, 2022, announcement that Amgen and ChemoCentryx, Inc. signed a definitive agreement pursuant to which Amgen would acquire ChemoCentryx. ChemoCentryx filed its Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, on August 8, 2022. About ChemoCentryx ChemoCentryx is a biopharmaceutical company commercializing and developing new medications for inflammatory and autoimmune diseases and cancer. 

    8/9/22 8:30:00 AM ET
    $CCXI

    ChemoCentryx to Hold Second Quarter 2022 Financial Results Conference Call on Tuesday, August 9, 2022

    SAN CARLOS, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ:CCXI), today announced that the Company's second quarter 2022 financial results will be released after market close on Tuesday, August 9, 2022. ChemoCentryx executive management will host a conference call and webcast beginning at 5:00 p.m. Eastern Time on August 9, 2022 to discuss these results and to answer questions. To participate by telephone, please dial (800) 715-9871 (Domestic) or (646) 307-1963 (International). The conference ID number is 9726781. A live and archived audio webcast can be accessed through the Investors section of the Company's website at www.ChemoCentryx.com. The archived webcast wil

    8/2/22 4:05:00 PM ET
    $CCXI